AFFILIATIONS
1 Broad Institute, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Mass General Brigham, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Broad Institute, Cambridge, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Mass General Brigham, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Mass General Brigham, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Broad Institute, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
11 Broad Institute, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
12 Broad Institute, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Broad Institute, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham, Boston, Massachusetts, United States
20 Broad Institute, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Mass General Brigham, Boston, Massachusetts, United States
ABSTRACT
Background: Precursor-to-malignancy research (e.g., MGUS to multiple myeloma) depends on biobanks that accumulate large, longitudinally collected sample cohorts over years to decades. The research value of these biobanks hinges on having accurate, queryable inventory and reliable cross-platform sample traceability. Legacy inventory management via protocol-specific spreadsheets limits discoverability, reproducibility, and scalability as cohorts grow, slowing progress in early precursor-disease detection, biomarker discovery, and targeted therapeutic development. We describe the digitalization of a cryopreserved biobank of gammopathy precursor samples across 19 clinical protocols, migrated into a structured, integrated Laboratory Information Management System (LIMS; OpenSpecimen, Krishagni Solutions).
Methods: We migrated data for 10,684 participants, 32,410 visits, 53,028 collection tubes, and 419,079 total aliquots (330,207 registered/inventoried to date; 88,872 in progress) from fragmented, protocol- and specimen-type-specific spreadsheets into LIMS, in collaboration with the institutional Informatics and Analytics department. During migration, we resolved 8,788 cross-platform sample ID mismatches and corrected 5,706 duplicate participant records. Previously split parent/derived protocols per cohort were consolidated into single protocols with a standardized cohort field, and cohort nomenclature was harmonized across platforms. Participant demographics and protocol IDs, entered in real time by clinical research coordinators at participant recruitment into the clinical registration system, were automatically synced with the LIMS, eliminating manual transcription. Physical inventory was reconfigured for freezer-location barcode scanning in LIMS. A structured technology-tagging workflow (capturing technology type, file location, sample/pool IDs, and date; tagging is ongoing) was implemented and linked to derived-specimen records in LIMS for mass spectrometry (n=1,472), spatial transcriptomics (n=49), whole-genome sequencing (293 tumor, 265 germline), single-cell RNA-seq (n=780), and CHIP (Clonal Hematopoiesis of Indeterminate Potential) sequencing panels (n=425). Integration of the clinical database (REDCap) with the LIMS and electronic lab notebook (SciSure), and of cloud storage via GitHub-linked pipelines, is being evaluated.
Results: Sample registration transitioned from a hybrid system of software-based entry and manual spreadsheets lacking standardized aliquot-level identifiers to barcode-scan-only workflows requiring no transcription and a sophisticated electronic system that accounts for regulatory and compliance considerations for human subjects research. Project-level aliquot-count queries that previously took hours to days now return in under 5 minutes. ID normalization and duplicate-participant correction eliminated recurrent sources of manual data-entry error during sample registration, and enabled real-time, cross-protocol sample-list queries and more efficient harmonization of datasets pulled from the LIMS, OnCore (clinical trials system), SciSure, and REDCap for data reporting and shipment tracking. The digitized biobank is currently used across more than 30 research projects by 12 researchers, 7 technicians, 10 clinical research coordinators, 8 data specialists, and 6 managers/scientists, and supports biospecimen collection and management for 8 active clinical trial-associated correlative studies as well as 7 non-interventional studies, with samples spanning more than 20 years. Integration of real-time sample-location data with technology-specific annotations enables participant-level identification of samples with existing omics datasets, facilitating multiomic cohort construction, real-time sample-availability assessment, and improved traceability across interventional, non-interventional, and correlative studies.
Conclusion: Migrating a large, multi-protocol cryopreserved precursor-disease biobank into a structured LIMS, implemented through close scientific-IT collaboration, substantially improved sample traceability and query efficiency while eliminating manual transcription errors. By making large, well-annotated precursor-disease cohorts rapidly queryable, this infrastructure directly supports research into early precursor-disease detection, biomarker discovery, and targeted therapeutics, and offers a replicable, scalable model for other centers managing similar longitudinal cohorts.